000129564 001__ 129564
000129564 005__ 20241125101132.0
000129564 0247_ $$2doi$$a10.3390/healthcare12010010
000129564 0248_ $$2sideral$$a135845
000129564 037__ $$aART-2023-135845
000129564 041__ $$aeng
000129564 100__ $$aJavier-Ormazábal, Alberto
000129564 245__ $$aThe effectiveness of a single dry needling session on gait and quality of life in multiple sclerosis: a double-blind randomized sham-controlled pilot trial
000129564 260__ $$c2023
000129564 5060_ $$aAccess copy available to the general public$$fUnrestricted
000129564 5203_ $$aGait disorders are a major cause of disability and reduced health-related quality of life in people with multiple sclerosis (pwMS). Dry needling (DN) has demonstrated positive results to improve gait parameters in patients with stroke. The main aim of this study was to evaluate the effect of a single session of DN in the gait performance of pwMS. Methods: A double-blind parallel randomized sham-controlled pilot trial was conducted. Study participants received a single session of active DN or sham DN in the gastrocnemius medialis muscle. Pre-treatment and immediately post-treatment measurements were taken, as well as at one and four weeks after the intervention. Outcomes related to gait performance (Timed 25-Foot Walk), self-perceived walking capacity (Multiple Sclerosis Walking Scale), risk of falls (Timed Up and Go test), disability level (Expanded Disability Status Score) and quality of life (Multiple Sclerosis Quality of Life-54 questionnaire and Analogic Quality of Life scale) were evaluated. Results: 18 patients who had multiple sclerosis participated in the study. The group who received active DN showed within-group significant statistical differences immediately after treatment for gait performance (p = 0.008) and risk of falls (p = 0.008), as well as for self-perceived walking capacity at one week (p = 0.017) and four weeks (p = 0.011) and quality of life at four weeks (p = 0.014). Regarding the comparison between groups, only significant results were obtained in the physical domain of the quality of life at four weeks (p = 0.014). Conclusions: DN seems to be a promising therapeutic tool for the treatment of gait disorders in pwMS. However, when results were compared with sham DN, no differences were found.
000129564 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000129564 590__ $$a2.4$$b2023
000129564 592__ $$a0.606$$b2023
000129564 591__ $$aHEALTH POLICY & SERVICES$$b49 / 118 = 0.415$$c2023$$dQ2$$eT2
000129564 593__ $$aHealth Policy$$c2023$$dQ2
000129564 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b73 / 174 = 0.42$$c2023$$dQ2$$eT2
000129564 593__ $$aLeadership and Management$$c2023$$dQ2
000129564 593__ $$aHealth Informatics$$c2023$$dQ3
000129564 593__ $$aHealth Information Management$$c2023$$dQ3
000129564 594__ $$a3.5$$b2023
000129564 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000129564 700__ $$aGonzález-Platas, Montserrat
000129564 700__ $$aJiménez-Sosa, Alejandro
000129564 700__ $$0(orcid)0000-0002-9201-0120$$aHerrero, Pablo$$uUniversidad de Zaragoza
000129564 700__ $$0(orcid)0000-0002-6506-6081$$aLapuente-Hernández, Diego$$uUniversidad de Zaragoza
000129564 7102_ $$11006$$2413$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Fisioterapia
000129564 773__ $$g12, 10 (2023), 1-12$$pHealthcare (Basel)$$tHealthcare (Switzerland)$$x2227-9032
000129564 8564_ $$s1737055$$uhttps://zaguan.unizar.es/record/129564/files/texto_completo.pdf$$yVersión publicada
000129564 8564_ $$s2768499$$uhttps://zaguan.unizar.es/record/129564/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000129564 909CO $$ooai:zaguan.unizar.es:129564$$particulos$$pdriver
000129564 951__ $$a2024-11-22-11:59:13
000129564 980__ $$aARTICLE